Eloxx Pharmaceuticals, Inc.
ELOXD
OTC PK
| 03/31/2026 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -- | -38.98% | -49.00% | -47.13% | -37.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -47.15% | -36.91% | -20.60% | 6.72% |
| Operating Income | -- | 47.15% | 36.91% | 20.60% | -6.72% |
| Income Before Tax | -- | 44.82% | 55.96% | 45.95% | 31.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -- | 44.82% | 55.96% | 45.95% | 31.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | 44.82% | 55.96% | 45.95% | 31.15% |
| EBIT | -- | 47.15% | 36.91% | 20.60% | -6.72% |
| EBITDA | -- | 47.16% | 36.90% | 20.57% | -6.76% |
| EPS Basic | -- | 45.10% | 62.00% | 58.95% | 52.96% |
| Normalized Basic EPS | -- | 46.67% | 41.43% | 38.67% | 30.11% |
| EPS Diluted | -- | 45.07% | 61.98% | 58.93% | 52.95% |
| Normalized Diluted EPS | -- | 46.67% | 41.43% | 38.67% | 30.11% |
| Average Basic Shares Outstanding | -- | 0.69% | 6.38% | 24.08% | 48.77% |
| Average Diluted Shares Outstanding | -- | 0.69% | 6.38% | 24.08% | 48.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |